Cardiovascular Diseases Clinical Trial
Official title:
Pragmatic Randomized Controlled Trial of the Cardiovascular Health Awareness Program (CHAP) in Subsidized Social Housing
Verified date | March 2023 |
Source | McMaster University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project aims to improve the cardiovascular health of seniors living in subsidized housing by implementing the successful community-based Cardiovascular Health Awareness Program (CHAP). CHAP is a patient-centred, interdisciplinary, multi-pronged, community-led CVD and stroke prevention and management program designed to prevent and reduce the impact of cardiovascular disease in older adults. The program addresses common cardiovascular disease risk factors, such as smoking, physical activity and poor diet by raising awareness of health and community resources available to encourage self-care and appropriate management of cardiovascular disease. A randomized controlled trial will be used to evaluate the impact of CHAP on healthcare utilization by older adults living in subsidized housing.
Status | Completed |
Enrollment | 2742 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years and older |
Eligibility | Building Inclusion Criteria: - Approximately 50-200 apartment units - Majority of residents are 55 years of age or older. - Unique postal code - Availability of at least one building with similar characteristics for matching/randomization Individual Inclusion Criteria - Resides in a study building - Aged 55 years or older - Speaks and reads English or French Note: Younger residents will be allowed to take part in the program but their data will not be included in the analysis. Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
Canada | Centre de recherche du CHUM | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
McMaster University | Université de Montréal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cardiovascular Risk - Change in blood pressure | Change in measured blood pressure (automated, validated device) | Baseline and 1 year | |
Other | Cardiovascular Risk - Change in body mass index | Change in body mass index calculated from height and weight (self-reported) | Baseline and 1 year | |
Other | Cardiovascular Risk - Change in waist circumference | Change in waist circumference (measured with measuring tape) | Baseline and 1 year | |
Other | Cardiovascular Risk - Change in diabetes risk score | Change in diabetes risk score (CANRISK questionnaire) | Baseline and 1 year | |
Primary | Healthcare Utilization Composite - Change in CVD-related emergency department visits and hospitalizations | Change in rate of CVD-related emergency department visits and hospitalizations by postal code from administrative databases (Building-level analysis) | Monthly from 1 year pre-intervention to 1 year post-intervention | |
Secondary | Healthcare Utilization - Change in all-cause emergency department visits | Change in rate of all-cause emergency department visits by postal code from administrative | Monthly from 1 year pre-intervention to 1 year post-intervention | |
Secondary | Healthcare Utilization - Change in all-cause hospitalizations | Change in all-cause hospitalization rates by postal code from administrative data (building-level) | Monthly from 1 year pre-intervention to 1 year post-intervention | |
Secondary | Change in quality of life | Measured using EQ-5D-5L | Baseline and 1 year | |
Secondary | Quality-Adjusted Life Years (QALYs) | Calculated from EQ-5D-5L at two time points and Canadian value sets | 1 year (post-intervention) | |
Secondary | Cost-effectiveness | Calculated from program cost data and health outcomes | 1 year (post-intervention) | |
Secondary | Participant experience of the CHAP intervention | Participant experience of the intervention will be evaluated through qualitative individual interviews and focus groups of residents. | 1 year (post-intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|